A sponsor company running a suite of early access programs discovered critical gaps in oversight, safety reporting, and HCP accountability — prompting a structured audit-led intervention.

A start-up biotech company developing an innovative investigational drug product faced growing challenges around oversight, data integrity, and inspection readiness as it moved into later phase development.